Biocon slammed with OAI; Hong Kong looks to Wuxi for ADC abilities; Tanvex Pharma launches CDMO services 

Wel­come to End­points News’ man­u­fac­tur­ing roundup, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions and more.

This week we saw Bio­con Bi­o­log­ics in com­mu­ni­ca­tion with the FDA over an OAI (of­fi­cial ac­tion in­di­ca­tion) af­ter prob­lem­at­ic in­spec­tions at its Malaysian fa­cil­i­ty and new plat­form launch­es from the likes of WuXi Bi­o­log­ics and Lalle­mand Health So­lu­tions.

We ze­ro in on mul­ti­ple part­ner­ships, in­clud­ing WuXi XDC boost­ing its bio­con­ju­gate ca­pa­bil­i­ties in Hong Kong as well as a few launch­es and merg­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.